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Abstract The implantation of chondrocytes, seeded
on matrices such as hyaluronic acid or collagen mem-
branes, is a method that is being widely used for the
treatment of chondral defects. The aim of the present
study was to evaluate the distribution, viability and
phenotype expression of the cells seeded on a collagen
membrane just at the time of the implantation. Twelve
patients who were suffering from articular cartilage
lesions were treated by the MACI
  procedure. The
residual part of each membrane was tested by colori-
metric assay (MTT) and histochemical and ultrastruc-
tural analyses were carried out. In all of the samples a
large number of viable cells, quite homogenously dis-
tributed, was detected. The cells expressed the markers
of the differentiated hyaline chondrocytes. These data
reassure in that the MACI procedure provides a suit-
able engineered tissue for cartilage repair, in line with
the clinical evidences emerging in the literature.
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Introduction
Autologous chondrocyte implantation (ACI) is an
established method for the treatment of chondral de-
fects [6]. Some prospective studies have demonstrated
subjective and objective improvement in joint function
at 12 months after surgery [3, 13]. MRI, second-look
surgery and biopsies have shown the formation of
nearly normal cartilage in a good number of patients
[13, 18, 19]. On the basis of these results, ACI may be
considered one of the most effective treatments of
articular cartilage lesions. However, this method is not
devoid of some problems with regard to, for example,
the wide surgical approach, the demanding technique,
the presence of periosteal ﬂap and the cell-holding in
site [14, 16].
In order to overcome some of these hurdles, new
tissue engineering techniques, widely used nowadays,
have been developed using chondrocytes seeded on
biological matrices such as hyaluronic acid [15]o r
collagen membranes [7] or atelocollagen gel [17]. De-
spite the wide diffusion of these methods, there are still
some areas that would need better clariﬁcation. The
presence of numerous, viable and well-differentiated
cells at surgery is an essential requisite for the success
of all these methods. It has been shown that autologous
chondrocytes in suspension before implantation are
able to maintain their differentiated phenotype and are
capable of proliferating fairly well [9, 20]. On the other
hand, little has been reported so far about cell char-
acterization in membrane-seeded ACI techniques.
The aim of the present study was to evaluate the
distribution, viability and phenotype expression of the
cells seeded on a collagen membrane just at the
moment of the implantation.
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  Springer-Verlag 2006Materials and methods
In 2003, 12 consecutive patients, 8 males and 4 females,
mean age of 34 years, suffering from cartilage lesions of
the knee (10 cases) and the ankle (2 cases), underwent a
collagenic scaffold-based ACI procedure (MACI
 -
Verigen, D). Autologous chondrocytes were isolated at
the Verigen laboratories from cartilage slices obtained
from non-bearing areas of the patients’ joints during a
preliminary arthroscopic surgery. Cells were propa-
gated in monolayer cultures in autologous serum for 2
or 3 weeks, according to the cellular growth rate, and
were passaged on average 3 times to obtain at least
10 · 10
6 cells. Cells were then seeded on 20 cm
2 type I/
III collagen membrane of porcine origin. The cell-see-
ded membranes were implanted in cartilage defects by
means of either arthroscopic or mini-open surgery,
using ﬁbrin glue to ensure adhesion. At each implan-
tation, the residual part of the membrane was collected
and tested for cell viability, and histochemical and
ultrastructural analyses were also performed.
Cell viability analysis
Cell viability was evaluated by MTT (dimethylthiazol-
diphenyltetrazol bromide; thiazolil blue) colorimetric
assay. MTT (Sigma, Italy) is a water soluble tetrazo-
lium salt that yields a yellowish solution when prepared
in medium lacking in phenol red (RTMI 1640, Sigma).
Dissolved MTT is converted to an insoluble purple
formazan by cleavage of the tetrazolium ring by the
active mitochondrial dehydrogenases of living cells.
The MTT solution (5 mg MTT/ml medium) was added
to three samples (1 cm
2) of each membrane, being
assayed to equal 1/10 of the original culture medium
volume, and incubated for 3 h. The solution was then
removed and acidic isopropanol (0.04–0.1 N HCl in
absolute isopropanol) was added to solubilize the stain.
The results were evaluated by means of the spec-
trophotometric assay (570 nm), yielding absorbance as
a function of viable cell number.
Histochemical and immunohistochemical analysis
The samples were ﬁxed by immersion in 4% para-
formaldehyde in 0.1 M phosphate buffer, pH 7.4, at
4 C and then embedded in parafﬁn. Specimens were
stained with safranin-O. For the immunohistochemis-
try, non-speciﬁc binding was blocked with 3% normal
goat serum in a phosphate-buffered saline (PBS), pH
7.4, for 30 min at room temperature; slides were then
incubated overnight with primary antibodies at 4 C.
Sections were incubated with polyclonal antibodies
anti S-100 protein (Dako, Italy), a cytoplasmatic mar-
ker of chondrocyte phenotype, diluted at 1:3,000, anti-
collagen type I (Monosan, The Netherlands) and II
(Calbiochem-Oncogene, CA, USA) at 1:150, and
monoclonal antibodies anti chondroitin sulphate
(chondroitin-S) (Sigma) at 1:200. Rabbit and mouse
immunoglobulins, at the same dilutions as the primary
antibodies, were used as controls. After three washes
with Tris–HCl (0.05 M, pH 7.6), revelation of the
reactions was accomplished by DAKO LSAB + kit,
HRP. Stainings were viewed and photographed with a
Leica Microscope (Leica Cambridge Ltd., UK).
Ultrastructural analysis
For scanning electron microscopy (SEM), the mem-
branes were ﬁxed in 2% glutaraldeyde in 0.1 M caco-
dylate buffer (pH 7.4), post-ﬁxed in 1% osmium
tetroxide, dehydrated in increasing ethanol concen-
trations and then CPD-dried. They were mounted on
stubs and gold-sputtered. Specimens were observed
with a Philips 505 microscope.
Results
Cell viability analysis
The presence of numerous viable cells was observed in
all samples, with quite a homogeneous stain distribu-
tion, even if some of the areas revealed a greater
concentration of converted dye (Fig. 1).
Considerable variability was found in mean cell
numbers between the samples from different patients,
in relation to the different amounts of cells obtained
from cartilage slices and seeded on the membrane.
Fig. 1 Macroscopic view of human chondrocytes seeded on type
I, III collagen membrane after MTT incubation. The converted
blue dye shows the presence of numerous viable cells with quite
a homogeneous stain distribution
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younger patients (Fig. 2, Table 1).
Histochemical and immunohistochemical analysis
In all of the samples, chondrocytes that were grown on
the membrane were arranged in multi-layered sheets,
and sometimes invaded deeper into the matrix. The
cells appeared to be quite well differentiated, although
some had a ﬂattened morphology. They slightly stained
metachromatically for safranin O (Fig. 3), and clearly
immunoreacted with anti-S-100 protein (Fig. 4), type II
collagen (Fig. 5) and chondroitin-S antibodies. Only a
few cells stained for type I collagen.
Ultrastructural analysis
The membranes presented a dual appearance: there
was a smooth side with tightly packed ﬁbres and a
rougher side, a sparse layer, to which the cells were
adhered. Numerous cells ﬁrmly adhered to the mem-
brane and showed a round shaped morphology and a
rough surface (Fig. 6).
Discussion
Cell phenotype and proliferation analysis should be an
essential step in the evaluation of all tissue-engineered
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Fig. 2 The standard curve obtained from each membrane by
MTT colorimetric assay (see also Table 1 )
Table 1 The table shows the
mean viable cell number/cm
2
obtained from each
membrane by MTT
colorimetric assay
Patients’ characteristics and
the number of cells initially
seeded on each membrane
are also reported (see also
Fig. 2)
Case Joint Age Sex Seeded cells Viable cells/cm
2 (mean ± SD)
1 Knee 54 M 19 · 10
6 (7.52 ± 2.79) · 10
3
2 Knee 22 F 17 · 10
6 (12.94 ± 2.54) · 10
3
3 Knee 50 F 15.4 · 10
6 (17.82 ± 6.25) · 10
3
4 Knee 23 M 20.3 · 10
6 (100.28 ± 22.14) · 10
3
5 Knee 29 F 20.4 · 10
6 (110.07 ± 39.18) · 10
3
6 Knee 43 M 18.7 · 10
6 (5.34 ± 3.25) · 10
3
7 Knee 48 M 17.5 · 10
6 (4.74 ± 2.37) · 10
3
8 Ankle 42 F 18.2 · 10
6 (33.13 ± 25.92) · 10
3
9 Knee 19 M 21.6 · 10
6 (99.54 ± 25) · 10
3
10 Knee 35 M 20 · 10
6 (103.81 ± 37.26) · 10
3
11 Ankle 39 M 19 · 10
6 (79.48 ± 62.57) · 10
3
12 Knee 13 M 20.1 · 10
6 (87.88 ± 55.17) · 10
3
Fig. 3 Human chondrocytes seeded on type I, III collagen
membrane before the implantation. Numerous cells are located
on the membrane and deeper in the matrix forming a multi-layer
engineered tissue. (Safranin O stain, ·200)
Fig. 4 Human chondrocytes seeded on type I, III collagen
membrane. A marked cytoplasmic immunoreaction for S-100
protein is evident (·400)
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or not-proliferating cells would not justify the thera-
peutic employment of these biotechnologies.
The chondrocyte culture may undergo a dediffer-
entiation process, consisting in a ﬁbroblast-like mor-
phology, a reduction of the type II collagen and
aggregating proteoglycans synthesis, and an increase of
type I collagen expression [1, 4]. Chondrocyte dedif-
ferentiation is common in monolayer cultures, while a
long phenotype maintenance is supported by the
presence of a tri-dimensional matrix [1, 4, 11]. The
chemical and ultrastructural characteristics of the ma-
trix may have great inﬂuence on the behaviour of
chondrocytes in culture. A Type I collagen membrane
appears to be a matrix endowed with such properties
which make that ideal and useful for cartilage tissue
engineering [8, 10].
MACI is a method for the treatment of articular
cartilage defects, that employs autologous chondro-
cytes expanded in monolayer culture, suspended, and
then seeded on type I–III collagen membrane. In a
previous study [9], we had observed that autologous
chondrocytes in suspension before implantation were
of ‘‘good cartilaginous quality’’ and that they possessed
an excellent proliferation capacity. Zheng et al. [20]
conﬁrmed that cells in ACI procedure maintained
chondrocyte phenotype and showed a low apoptotic
rate. To our knowledge, there is no previous reference
to the analysis of the phenotype and the proliferation
activity of human chondrocytes before MACI implan-
tation. Data about cell number and viability, but not
about cell phenotype and distribution are provided by
Verigen’s laboratory for each implant. It should,
however, be remembered that it is quite possible that
the presence of a membrane like the one found in the
MACI technique could interfere with cell behaviour
and modify phenotype expression.
The present study has demonstrated that the autol-
ogous chondrocytes that were analysed adhered to the
membrane and had quite a homogenous distribution.
These cells were viable in all the cases analysed, as
shown by the spectrophotometric assay. The differ-
ences observed among patients in the number of cells
seeded on the membrane and those found to be viable
are probably due to several factors. In the ﬁrst place,
the amount of tissue collected from patients and sent to
the laboratory for culture was variable. The cellularity
of cartilage tissue and the proliferation capacity of
chondrocytes in identical culture conditions are also
quite variable between subjects, and this variability
cannot merely be explained with age, but is more likely
to stem from a number of characteristics that deﬁne
tissue ‘‘quality’’ [5, 12].
We did not investigate whether during monolayer
culture chondrocytes underwent dedifferentiation,
however, other authors [20] demonstrated that cells
grown in monolayer with the same culture conditions
maintained a differentiated phenotype. Moreover, we
felt it was important to establish the phenotypical
expression of chondrocytes seeded on the I/III collagen
membrane, since those are the cells that are then im-
planted, independently of what has taken place in the
previous steps of the procedure. The positive immu-
nostaining for S-100 protein, chondroitin-S, type II, but
not type I collagen, conﬁrms that cells maintained the
characteristics of differentiated hyaline chondrocytes
at the moment they were implanted.
These data reassure that the MACI procedure can
indeed provide a suitable engineered tissue for carti-
lage repair, in line with the mid-term clinical results
Fig. 5 Human chondrocytes seeded on type I, III collagen
membrane. Cells express a positive immunoreaction for type II
collagen, while the membrane remains unstained (·400)
Fig. 6 Scanning electron micrograph of human chondrocytes
seeded on type I, III collagen membrane. Numerous cells
(arrows) ﬁrmly adhere to the membrane and show a round
shaped morphology and a rough surface (·7,500)
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123described in the literature so far [2, 7]. Nevertheless,
clinical and histological results of this method to attain
stable clinical recovery and a hyaline-like cartilaginous
scar are auspicated to substantiate these evidences in
the long term.
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